Jupiter Neurosciences

Jupiter Orphan Therapeutics, Inc. (JOT) is a clinical-stage drug platform company dedicated to developing treatments for rare diseases and central nervous system disorders. The company operates in the biopharmaceutical sector, focusing on reformulating the well-known compound resveratrol to create therapeutically effective medications without gastrointestinal side effects. JOT's unique platform product is the first and only resveratrol formulation capable of delivering high plasma levels, crossing the blood-brain barrier, and providing anti-inflammatory benefits and mitochondrial biogenesis boosts. This makes it particularly promising for treating conditions such as Friedreich's Ataxia and Alzheimer's Disease.

JOT serves patients suffering from rare diseases and central nervous system disorders, aiming to improve their quality of life through innovative treatments. The company generates revenue through the development and commercialization of its patented drug formulations, leveraging human data from various indications and FDA-approved Investigational New Drug (IND) applications.

Keywords: resveratrol, rare diseases, central nervous system, drug platform, clinical-stage, FDA-approved, anti-inflammatory, mitochondrial biogenesis, Friedreich's Ataxia, Alzheimer's Disease.